MET and non-small cell lung carcinoma: The GEOMETRY mono-1 phase II clinical trial tested the efficacy of daily administration of 400 mg of capmatinib in patients with various MET alterations, and the principal subgroups were composed either of patients with MET exon 14-mutated NSCLC who received 2 prior lines of treatment (cohort 4) or treatment-naïve patients (cohort 5b).